Merus (NASDAQ:MRUS) Receives Consensus Rating of “Buy” from Analysts

Merus (NASDAQ:MRUS) has earned an average rating of “Buy” from the twelve analysts that are currently covering the company, Marketbeat reports. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $80.20.

Several research firms recently commented on MRUS. Bank of America reiterated a “buy” rating and set a $76.00 target price on shares of Merus in a research report on Tuesday, June 25th. Citigroup lifted their price target on shares of Merus from $70.00 to $93.00 and gave the stock a “buy” rating in a report on Wednesday, June 26th. Truist Financial raised their target price on Merus from $69.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, June 4th. BMO Capital Markets upped their price target on Merus from $84.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. Finally, Stifel Nicolaus raised their price objective on Merus from $90.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, June 17th.

Merus Stock Performance

Shares of NASDAQ:MRUS opened at $47.50 on Thursday. Merus has a 52-week low of $19.81 and a 52-week high of $61.61. The company has a market capitalization of $3.24 billion, a PE ratio of -17.15 and a beta of 1.12. The company has a fifty day moving average of $51.60 and a 200-day moving average of $49.97.

Merus (NASDAQ:MRUS) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.05). The firm had revenue of $7.33 million during the quarter, compared to the consensus estimate of $9.64 million. Merus had a negative net margin of 476.41% and a negative return on equity of 36.33%. On average, equities analysts forecast that Merus will post -3.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Merus

Several institutional investors have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC increased its stake in shares of Merus by 37.7% in the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 343 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Merus in the first quarter worth $72,000. SG Americas Securities LLC bought a new stake in Merus in the first quarter valued at $108,000. Farallon Capital Management LLC acquired a new position in shares of Merus during the second quarter valued at about $237,000. Finally, ProShare Advisors LLC bought a new position in shares of Merus during the 2nd quarter worth about $242,000. 96.14% of the stock is owned by institutional investors and hedge funds.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.